Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2024 | The safety and efficacy of elranatamab in patients with R/R AL amyloidosis

Pedro Vianna • 26 Sep 2024
IMS 2024
Amyloidosis Rare Diseases Antibodies Elranatamab

Pedro Vianna, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of elranatamab in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. The study found that off-label use of elranatamab led to rapid and deep hematological responses with a tolerable safety profile. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pedro Vianna

The key unmet needs in the frontline and R/R setting in amyloidosis
1:12
The key unmet needs in the frontline and R/R setting in amyloidosis
Pedro Vianna • 26 Sep 2024
The value of early diagnosis in amyloidosis and the impact of a delayed diagnosis for patients
1:15
The value of early diagnosis in amyloidosis and the impact of a delayed diagnosis for patients
Pedro Vianna • 26 Sep 2024
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
1:14
Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics
Pedro Vianna • 26 Sep 2024

Related Videos

Promising therapies and approaches for systemic mastocytosis
0:58
Promising therapies and approaches for systemic mastocytosis
Deepti Radia • 12 Jun 2026
The hottest updates in MPNs from EHA 2026
4:52
The hottest updates in MPNs from EHA 2026
Prithviraj Bose • 11 Jun 2026
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
4:17
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
Maria Teresa Voso • 12 Jun 2026
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
The content of VJHemOnc is intended for healthcare professionals